Methods Matter: Standard production platforms for recombinant AAV produce chemically and functionally distinct vectors

May 22, 2020

Rumachik, N., Malaker, S., Poweleit, N., et al.

Methods and Clinical Development 2020, vol: 18(11) doi: 10.1016/j.omtm.2020.05.018

Abstract

Different approaches are used in the production of recombinant adeno-associated virus (rAAV). The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells. Unexplained differences in vector performance have been seen clinically and preclinically. Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters. We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice. Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms. Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans. Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05–0.0001), in various mouse tissues in vivo (p < 0.03–0.0001), and in human liver in vivo (p < 0.005). These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.

View Publication

Topics: Prometheus, nanoDSF, Gene Therapy, Publications

Previous Video
Maximize stability & function of SARS-CoV-spike protein and ACE2 receptor using Monolith & Prometheus
Maximize stability & function of SARS-CoV-spike protein and ACE2 receptor using Monolith & Prometheus

Dr. Leah Pandiscia and Dr. Daniel Turman review how to integrate the Prometheus Panta and Monolith instrume...

Up next
Mechanisms for protein aggregation and stabilization in solution, during freezing and drying, and at interfaces
Mechanisms for protein aggregation and stabilization in solution, during freezing and drying, and at interfaces

Learn about the causes of protein aggregation and how to implement the best solutions to enhance protein st...

Ready to tackle your challenging stability characterizations?

Discover tools